Answers are grounded in this paper and cite their sources.
Retrospective analysis highlights the efficacy of different doses of venetoclax combined with azacitidine in ndAML patients, suggesting optimal tolerance may vary.
Introduction The combination of venetoclax and azacitidine shows significant efficacy in newly diagnosed acute myeloid leukemia (ndAML) patients. In specific contexts, low-dose venetoclax may be preferred to optimize patient tolerance.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: